Akèy › Lukemi lenfositè kwonik › North Carolina › Winston-Salem
Etid klinik pou Lukemi lenfositè kwonik nan Winston-Salem, NC
8 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Winston-Salem (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
- Research Site, Winston-Salem
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- Atrium Health Wake Forest Baptist, Winston-Salem
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 3
- Atrium Health Wake Forest Baptist, Winston-Salem
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- Novant Health Cancer Institute, Winston-Salem
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Ap rekriteFaz 2
- Research Site, Winston-Salem
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Ap rekriteEtid obsèvasyon
- Wake Forest Baptist Health, Winston-Salem
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 3
- Atrium Health Wake Forest Baptist Medical Center /ID# 273142, Winston-Salem
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 2
- Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN18 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Cincinnati, OH14 etid
Lòt etid nan Winston-Salem
- Kansè (tout kalite)19 etid
- Leksemi mieloïd egi18 etid
- Myelom Miltip14 etid
- Kansè nan tete14 etid
- Maladi kadyovaskilè14 etid
- Kansè Poumon ki pa ti selil12 etid
- BPCO10 etid
- Kansè ovè10 etid
- Dyabèt Tip 29 etid
- Sendwòm myelodisplastik9 etid
- Gliyoblastòm8 etid
- Kansè poumon8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.